Nephros Inc. (NEPH) 0.5500 $NEPH
Nephros Announces Successful Completion of $3 Million Rights Offering
Business Wire - Thu Dec 18, 3:10PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the successful completion of its rights offering.
Nephros Provides Corporate Update
Business Wire - Mon Dec 08, 3:49PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.
Nephros Reports Third Quarter 2014 Financial Results and Announces Launch of Rights Offering
PR Newswire - Fri Nov 14, 3:05PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today financial results for the three and nine months ended September 30, 2014 and the launch of its previously announced rights offering.
Nephros Receives 510(k) Clearance for DSU-H and SSU-H Ultrafilters
PR Newswire - Tue Oct 28, 3:05PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today announced that the Company has received 510(k) clearance from the Food and Drug Administration ("FDA"
to market its DSU-H and SSU-H Ultrafilters for use in the hospital setting.
Nephros Completes Bridge Financing
PR Newswire - Wed Sep 03, 3:15PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that the company has entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company's largest shareholder.
Nephros posts lower net loss of USD654,000 for Q2 2014
M2 - Mon Aug 18, 7:36AM CDT
Medical device company Nephros (OTC BB:NEPH) declared on Friday a net loss of USD654,000, or USD0.03 per share for the three months ended 30 June 2014.
Nephros Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 14, 5:17PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three and six months ended June 30, 2014.
Nephros Announces FDA 510(k) Submission of DSU-H and SSU-H Ultrafilters to be used to filter EPA quality drinking water to remove microbiological contaminants and waterborne pathogens
PR Newswire - Mon Jun 30, 3:05PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has submitted to the U.S. Food and Drug Administration (FDA), for 510(k) clearance, the DSU-H and SSU-H Ultrafilters to filter Environmental Protection Agency (EPA) quality drinking water to remove microbiological contaminants and waterborne pathogens.
Nephros Announces Successful Completion of $3 Million Rights Offering
Business Wire - Thu Dec 18, 3:10PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the successful completion of its rights offering.
Nephros Provides Corporate Update
Business Wire - Mon Dec 08, 3:49PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.
Nephros Reports Third Quarter 2014 Financial Results and Announces Launch of Rights Offering
PR Newswire - Fri Nov 14, 3:05PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today financial results for the three and nine months ended September 30, 2014 and the launch of its previously announced rights offering.
Nephros Receives 510(k) Clearance for DSU-H and SSU-H Ultrafilters
PR Newswire - Tue Oct 28, 3:05PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today announced that the Company has received 510(k) clearance from the Food and Drug Administration ("FDA"
to market its DSU-H and SSU-H Ultrafilters for use in the hospital setting. Nephros Completes Bridge Financing
PR Newswire - Wed Sep 03, 3:15PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that the company has entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company's largest shareholder.
Nephros posts lower net loss of USD654,000 for Q2 2014
M2 - Mon Aug 18, 7:36AM CDT
Medical device company Nephros (OTC BB:NEPH) declared on Friday a net loss of USD654,000, or USD0.03 per share for the three months ended 30 June 2014.
Nephros Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 14, 5:17PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three and six months ended June 30, 2014.
Nephros Announces FDA 510(k) Submission of DSU-H and SSU-H Ultrafilters to be used to filter EPA quality drinking water to remove microbiological contaminants and waterborne pathogens
PR Newswire - Mon Jun 30, 3:05PM CDT
Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has submitted to the U.S. Food and Drug Administration (FDA), for 510(k) clearance, the DSU-H and SSU-H Ultrafilters to filter Environmental Protection Agency (EPA) quality drinking water to remove microbiological contaminants and waterborne pathogens.
